BlackRock Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

BlackRock Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17K	Hold	1,315	–	–	﹤0.01%	3494
2016 Q3	$24K	Hold	1,315	–	–	﹤0.01%	3415
2016 Q2	$14K	Sell	1,315 -2,493	-65%	-$49K	﹤0.01%	3525
2016 Q1	$72K	Buy	3,808 +511	+15%	+$9.83K	﹤0.01%	3062
2015 Q4	$88K	Sell	3,297 -1,729	-34%	-$60K	﹤0.01%	2983
2015 Q3	$229K	Sell	5,026 -288	-5%	-$10.9K	﹤0.01%	2648
2015 Q2	$171K	Buy	5,314 +15	+0.3%	+$436	﹤0.01%	2881
2015 Q1	$169K	Buy	5,299 +867	+20%	+$29.3K	﹤0.01%	2775
2014 Q4	$168K	Sell	4,432 -230	-5%	-$6.33K	﹤0.01%	2740
2014 Q3	$123K	Sell	4,662 -115	-2%	-$3.04K	﹤0.01%	2896
2014 Q2	$141K	Buy	4,777 +331	+7%	+$10.7K	﹤0.01%	2855
2014 Q1	$165K	Buy	4,446 +381	+9%	+$14.5K	﹤0.01%	2770
2013 Q4	$168K	Buy	4,065 +313	+8%	+$12.2K	﹤0.01%	2755
2013 Q3	$199K	Buy	3,752 +44	+1%	+$2.56K	﹤0.01%	2554
2013 Q2	$198K	Buy	+3,708	New	+$185K	﹤0.01%	2471

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors's NAVB Position: Q4 2016 in Review

BlackRock Advisors held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q4 2016 at 1,315 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

BlackRock Advisors first reported a position in NAVB in Q2 2013 and has held it in 15 quarters since. The position peaked at $229K in Q3 2015. 55 funds tracked by Wall St. Rank hold NAVB as of Q4 2016.

BlackRock Advisors held 1,315 shares of Navidea Biopharmaceuticals Inc. worth $17K as of Q4 2016.
BlackRock Advisors left its Navidea Biopharmaceuticals Inc. share count unchanged in Q4 2016.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3494 holding.
BlackRock Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Navidea Biopharmaceuticals Inc. position peaked at $229K in Q3 2015.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.